ASCRS 2025 | International Ophthalmology Expert Presents Biocompatibility Evaluation of Eyedeal® xPIB Intraocular Lens
On the morning of April 26, the 51st Annual Meeting of the American Society of Cataract and Refractive Surgery (ASCRS) hosted its “Intraocular Lens (IOL) Design and Characteristics” sub-forum as scheduled. Renowned international ophthalmologist Professor Guy Kleinmann delivered an academic presentation titled “Biocompatibility Evaluation of a Novel Intraocular Lens Material”. He released the animal trial results of the next-generation Eyedeal® cross-linked polyisobutylene (xPIB) intraocular lens developed by Xi’an Eyedeal Medical Technology Co., Ltd., providing a detailed assessment of the product’s exceptional biocompatibility features.
The study conducted preclinical biocompatibility assessments through IOL implantation in rabbit eyes. Results showed that the Eyedeal® xPIB IOL demonstrated no significant differences in tissue response of the uveal tract and capsular bag compared to the control group using the current industry-standard material—hydrophobic acrylic AcrySof® SA60AT (Alcon, Fort Worth, USA). Moreover, the Eyedeal® xPIB IOL showed a lower incidence of posterior capsular opacification (PCO) and Soemmerring’s ring formation, highlighting its excellent overall biocompatibility.
“Whether at one week or six weeks post-operation, both the Eyedeal® xPIB test group and the control group exhibited inflammatory responses within acceptable ranges, with no significant differences observed between them,” noted Professor Guy Kleinmann. He emphasized that, in rabbit models, a six-week period corresponds to a human postoperative response cycle of approximately three to five years. Throughout the observation period, the Eyedeal® xPIB IOL demonstrated remarkable stability in both inflammation control and capsular bag condition.
About Professor Guy Kleinmann
Dr. Guy Kleinmann, MD, graduated from the John A. Moran Eye Center at the University of Utah and currently serves as the Head of the Cataract Division at Kaplan Medical Center in Israel. His primary areas of research include the retina, glaucoma, and cataract.
He has made numerous contributions to the field of ophthalmology, including the study of square-edge IOL designs to prevent posterior capsule opacification and the management of ocular complications in type 1 diabetes, such as diabetic retinopathy. Professor Kleinmann has an H-index of 18, with 74 published papers and a total of 1,002 citations. He is a member of several prestigious professional organizations, including the Association for Research in Vision and Ophthalmology (ARVO), the American Society of Cataract and Refractive Surgery (ASCRS), the American Academy of Ophthalmology (AAO), and the Israel Ophthalmological Society.